Momenta Pharmaceuticals, Inc. (MNTA)

[biopearl]

With such positive data from DEFINE and with the CONFIRM data looming (2nd half or 2011) as a comparator to copaxone, doesn't it seem that TEVA is just expecting a paradigm shift to oral meds to solve their copaxone problem? Even if FDA approval comes for Momenta's product can anyone get a handle as to the efficacy of the oral agents and the impact on the copaxone market? Dew, could you please comment and would you now in the face of these studies recommend a more defensive posture re MNTA? thanks bp